tiprankstipranks
Advertisement
Advertisement

NKTX Stock Latest News

Nkarta initiated with a Buy at TD Cowen
The FlyNkarta initiated with a Buy at TD Cowen
20d ago
NKTX
Phil Nadeau Reiterates Buy on Nkarta, Citing Differentiated NK Cell Platform and CD19 CAR NK Therapy as Key Long-Term Value Drivers
PremiumRatings
Phil Nadeau Reiterates Buy on Nkarta, Citing Differentiated NK Cell Platform and CD19 CAR NK Therapy as Key Long-Term Value Drivers
20d ago
NKTX
Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay
PremiumCompany Announcements
Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay
1M ago
8K
NKTX
Nkarta price target lowered to $9 from $25 at Evercore ISI
PremiumThe Fly
Nkarta price target lowered to $9 from $25 at Evercore ISI
2M ago
NKTX
Nkarta Buy Rating Reaffirmed as NKX019 Autoimmune Trials Advance; $16 Price Target Maintained
PremiumRatings
Nkarta Buy Rating Reaffirmed as NKX019 Autoimmune Trials Advance; $16 Price Target Maintained
2M ago
NKTX
Nkarta reports Q1 EPS (37c), consensus (37c)
PremiumThe FlyNkarta reports Q1 EPS (37c), consensus (37c)
2M ago
NKTX
Nkarta (NKTX): Constructive Buy Rating on Leadership, Strategic Positioning, and Upcoming Value-Creating Milestones
Premium
Ratings
Nkarta (NKTX): Constructive Buy Rating on Leadership, Strategic Positioning, and Upcoming Value-Creating Milestones
3M ago
NKTX
Nkarta announces agreement with FDA on changes to Ntrust-1, Ntrust-2 trials
Premium
The Fly
Nkarta announces agreement with FDA on changes to Ntrust-1, Ntrust-2 trials
3M ago
NKTX
Nkarta price target lowered to $12 from $14 at Mizuho
PremiumThe Fly
Nkarta price target lowered to $12 from $14 at Mizuho
3M ago
NKTX
Buy Rating Initiated on NKX019’s Differentiated CAR‑NK Platform and De‑Risked Autoimmune Opportunity Ahead of 2026 Proof‑of‑Concept Data
PremiumRatings
Buy Rating Initiated on NKX019’s Differentiated CAR‑NK Platform and De‑Risked Autoimmune Opportunity Ahead of 2026 Proof‑of‑Concept Data
4M ago
NKTX
Nkarta price target raised to $11 from $10 at Needham
PremiumThe Fly
Nkarta price target raised to $11 from $10 at Needham
4M ago
NKTX
Nkarta Launches $100 Million At-the-Market Stock Offering
PremiumCompany Announcements
Nkarta Launches $100 Million At-the-Market Stock Offering
4M ago
8K
NKTX
Nkarta files $350M mixed securities shelf
PremiumThe FlyNkarta files $350M mixed securities shelf
4M ago
NKTX
Nkarta reports Q4 EPS (37c), consensus (29c)
Premium
The Fly
Nkarta reports Q4 EPS (37c), consensus (29c)
4M ago
NKTX
Is NKTX a Buy, Before Earnings?
Premium
Pre-Earnings
Is NKTX a Buy, Before Earnings?
4M ago
NKTX
Nkarta price target lowered to $11 from $12 at Stifel
PremiumThe Fly
Nkarta price target lowered to $11 from $12 at Stifel
8M ago
NKTX
Nkarta’s Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price
PremiumRatings
Nkarta’s Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price
8M ago
NKTX
Nkarta Advances NKX019 Program Amid Financial Stability
PremiumCompany Announcements
Nkarta Advances NKX019 Program Amid Financial Stability
8M ago
NKTX
Nkarta reports Q3 EPS (29c), consensus (30c)
PremiumThe Fly
Nkarta reports Q3 EPS (29c), consensus (30c)
8M ago
NKTX
Nkarta’s NKX019 Study: A Promising Step in Autoimmune Disease Treatment
PremiumCompany AnnouncementsNkarta’s NKX019 Study: A Promising Step in Autoimmune Disease Treatment
9M ago
NKTX
Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases
Premium
Company Announcements
Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases
9M ago
NKTX
Nkarta price target lowered to $12 from $14 at Stifel
Premium
The Fly
Nkarta price target lowered to $12 from $14 at Stifel
11M ago
NKTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >